Mironova Labs

Actives for Lash & Brow Serums

Prostaglandin analogs, non-PG alternatives, and cosmetic peptides for lash & brow formulation

For lash/brow serum brands sourcing prostaglandin analogs and non-PG alternatives from a single qualified supplier

Discuss Your Formulation Needs Hair Enhancement Actives Science Hub

15+

PG Analogs Available

≥98%

Purity Standard

Active Ingredients

PG + Non-PG

Dual Strategy

Supported by peer-reviewed research·US-manufactured·Multi-analog PG supply·Non-PG alternatives available·Regulatory-aware

The lash and brow serum market is navigating tightening prostaglandin regulations (EU SCCS 2026, Health Canada prohibition) while consumers demand effective alternatives. Mironova supplies both prostaglandin analogs for permissive markets and non-PG alternatives (Kopyrrol Aqua, cosmetic peptides) for regulated ones — all from a single US-based supplier.

Hair Actives Science Prostaglandin Catalog Hair Actives Catalog

Challenges & Solutions

Your Challenge. Our Answer.

We understand the specific problems you face — and we built solutions for each one.

The Problem

EU SCCS and Health Canada have flagged or restricted prostaglandin analogues in cosmetics, creating regulatory uncertainty for lash/brow serums

Mironova’s Answer

Mironova offers both prostaglandin analogs (for markets where permitted) and non-PG alternatives — so your brand can adapt to any regulatory environment

The Problem

Single-source prostaglandin supply creates business risk if that supplier faces quality or regulatory issues

Mironova’s Answer

Mironova manufactures multiple PG analogs in-house, providing supply diversification with consistent quality from one US facility

The Problem

Consumer awareness of prostaglandin side effects (periorbital fat loss, iris darkening) is driving demand for PG-free alternatives

Mironova’s Answer

Our non-PG hair enhancement actives (Kopyrrol Aqua, Kopexil Aqua) and cosmetic peptides offer alternative mechanisms without PG-associated concerns

Published Research

Published Evidence

Key findings from peer-reviewed literature relevant to your application.

EU Regulatory Landscape

SCCS concludes that prostaglandin analogues MDN, isopropyl cloprostenate, and DDDE cannot be considered safe in cosmetic products for eyelash/eyebrow growth.

EU SCCS Opinion SCCS/1680/25

Canada PG Prohibition

Prostaglandins, their salts, derivatives and analogues are listed as prohibited in cosmetic products in Canada.

Health Canada Cosmetic Ingredient Hotlist

Non-PG Mechanism: Collagen Modulation

DPO (aminexil) modulates lysyl hydroxylase mRNA expression, targeting the collagen maturation pathway — a mechanistically distinct approach from prostaglandins.

Mahé et al., Skin Pharmacology 1996

Market Context

Prostaglandin Regulation Is Reshaping the Lash Serum Market

The EU SCCS concluded in February 2026 that prostaglandin analogues MDN, isopropyl cloprostenate, and DDDE cannot be considered safe in cosmetic products intended to promote eyelash/eyebrow growth. Health Canada prohibits prostaglandins in cosmetics entirely. Consumer awareness of periorbital side effects (fat loss, iris pigmentation) is rising. Brands need both PG supply for permissive markets and non-PG alternatives for regulated ones — from a single, qualified supplier.

EU SCCS/1680/25 (Feb 2026); Health Canada Cosmetic Ingredient Hotlist

2026

EU SCCS final opinion published

15+

PG compounds in catalog

Product Catalog

Lash/Brow Serum Formulation Notes

diaminopyrimidines 0.2–1.5% (w/w); cosmetic peptides 1–50 ppm.

Typically 0.01–0.03% in finished lash serums — check regulatory status in your market before formulating.

Water-soluble actives (non-PG) require no organic co-solvents for periorbital application.

Myristoyl lipopeptides pair well in multi-target lash serums (keratin + growth phase support).

Compatible with common serum bases (HA, glycerin, panthenol).

pH stability range: 4.5–7.0 for peptide-containing formulations; PG analogs may require lower pH — consult technical data sheet.

For full mechanism data, formulation guidance, and evidence grading, please visit our Hair Enhancement Actives Science Hub.

Why Mironova

Your Advantage with Mironova

Dual PG + Non-PG Portfolio

Supply prostaglandin analogs for markets where permitted, and non-PG alternatives (Kopyrrol Aqua, peptides) for regulated markets. One supplier for both strategies.

15+ PG Compounds

Bimatoprost amide, latanoprost, isopropyl cloprostenate, tafluprost ethyl amide, and more. In-house manufacturing with ≥98% purity provides supply diversification.

Regulatory Navigation Support

We track PG regulatory developments across jurisdictions (EU, Canada, US FDA). Our technical team helps you select the right active strategy for your target markets.

Non-PG Periorbital Options

Water-soluble actives requiring no organic co-solvents for periorbital formulation. Peptide doses at 1–50 ppm offer a gentler formulation profile.

Request Technical Data

Get product specifications, CoA samples, and pricing for your evaluation.

FAQ

Frequently Asked Questions

Common technical questions about this product line, answered by our scientific team.

It depends on the market. The EU SCCS issued a negative safety opinion in February 2026 for specific PG analogs in lash/brow growth cosmetics. Health Canada prohibits the entire class. The US FDA evaluates products by their claims: “grows lashes” is a drug claim regardless of ingredient. We help you navigate market-specific requirements.

Our non-PG portfolio includes Kopyrrol Aqua (PDPO·OTZ, K₊ATP channel mechanism), Kopexil Aqua (DPO·OTZ, collagen modulation), Biotinoyl Tripeptide-1 (ECM remodeling), and myristoyl lipopeptides (keratin gene support). These address different follicular pathways without prostaglandin-associated risks.

Myristoyl Hexapeptide-16 has supplier-demonstrated data on eyelash appearance effects. Symrise-sourced studies cite 23% thickness improvement at 2 weeks and 61% density improvement at 28 days. These are supplier study results — independent verification for your specific formulation is recommended.

Propylene glycol and ethanol, common solvents for PG analogs, can cause irritation in the periorbital area. Our water-soluble PDPO·OTZ and DPO·OTZ forms dissolve directly in aqueous phases, enabling gentler formulations without organic co-solvents.